Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker INDP
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 22, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Chenhao Xu | 38.90M | 25.3% | SCHEDULE 13D/A ↗ |
| Oct 22, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Sino Lion Ventures Ltd | 38.90M | 25.3% | SCHEDULE 13D/A ↗ |
| Oct 22, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Dai Junyi | 11.25M | 7.3% | SCHEDULE 13D/A ↗ |
| Oct 22, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Yao Yun | 41.99M | 27.3% | SCHEDULE 13D/A ↗ |
| Oct 21, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Yang Ting | 9.95M | 6.5% | SCHEDULE 13D/A ↗ |
| Jun 26, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Chenhao Xu | 38.90M | 29.2% | SCHEDULE 13D/A ↗ |
| Jun 26, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Sino Lion Ventures Ltd | 38.90M | 29.2% | SCHEDULE 13D/A ↗ |
| Jun 26, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Dai Junyi | 11.25M | 8.4% | SCHEDULE 13D/A ↗ |
| Jun 26, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Yang Ting | 11.25M | 8.4% | SCHEDULE 13D/A ↗ |
| Jun 26, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Yao Yun | 41.99M | 31.5% | SCHEDULE 13D/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Deng Lina | 5.55M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Yang Ting | 11.25M | 9.9% | SCHEDULE 13D/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Dai Junyi | 11.25M | 9.9% | SCHEDULE 13D/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Xu Chenhao | 38.90M | 34.3% | SCHEDULE 13D/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | SINO LION VENTURES Ltd | 38.90M | 34.3% | SCHEDULE 13D/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Yao Yun | 41.99M | 37.1% | SCHEDULE 13D/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | INDP Indaptus Therapeutics, Inc. | SC-Sigma Global Partners, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | INDP Indaptus Therapeutics, Inc. | Mark Angelo | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | INDP Indaptus Therapeutics, Inc. | Yaii GP II, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | INDP Indaptus Therapeutics, Inc. | Yaii GP, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | INDP Indaptus Therapeutics, Inc. | Yorkville Advisors Global II, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | INDP Indaptus Therapeutics, Inc. | Yorkville Advisors Global, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | INDP Indaptus Therapeutics, Inc. | YA Global Investments II (U.S.), LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | INDP Indaptus Therapeutics, Inc. | YA II PN, Ltd. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Mar 30, 2026 | SCHEDULE 13D | INDP Indaptus Therapeutics, Inc. | Deng Lina | 5.55M | 5.0% | SCHEDULE 13D ↗ |
| Mar 30, 2026 | SCHEDULE 13D | INDP Indaptus Therapeutics, Inc. | Yang Ting | 11.25M | 10.1% | SCHEDULE 13D ↗ |
| Mar 30, 2026 | SCHEDULE 13D | INDP Indaptus Therapeutics, Inc. | Dai Junyi | 11.25M | 10.1% | SCHEDULE 13D ↗ |
| Mar 30, 2026 | SCHEDULE 13D | INDP Indaptus Therapeutics, Inc. | Xu Chenhao | 38.90M | 35.0% | SCHEDULE 13D ↗ |
| Mar 30, 2026 | SCHEDULE 13D | INDP Indaptus Therapeutics, Inc. | SINO LION VENTURES Ltd | 38.90M | 35.0% | SCHEDULE 13D ↗ |
| Mar 30, 2026 | SCHEDULE 13D | INDP Indaptus Therapeutics, Inc. | Yao Yun | 41.99M | 37.8% | SCHEDULE 13D ↗ |
| Mar 24, 2026 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | David E. Lazar | 2.06M | 47.9% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D | INDP Indaptus Therapeutics, Inc. | David E. Lazar | 111.00M | 98.0% | SCHEDULE 13D ↗ |
| Dec 30, 2025 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Jeffery A. Meckler | 273,103 | 12.7% | SCHEDULE 13D/A ↗ |
| Dec 30, 2025 | SCHEDULE 13D/A (amended) | INDP Indaptus Therapeutics, Inc. | Newman Michael James | 115,552 | 5.4% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13G | INDP Indaptus Therapeutics, Inc. | SC-Sigma Global Partners, LP | 1.41M | 10.0% | SCHEDULE 13G ↗ |
| Feb 18, 2025 | SCHEDULE 13G | INDP Indaptus Therapeutics, Inc. | Mark Angelo | 1.41M | 10.0% | SCHEDULE 13G ↗ |
| Feb 18, 2025 | SCHEDULE 13G | INDP Indaptus Therapeutics, Inc. | Yaii GP II, LLC | 1.41M | 10.0% | SCHEDULE 13G ↗ |
| Feb 18, 2025 | SCHEDULE 13G | INDP Indaptus Therapeutics, Inc. | Yaii GP, LP | 1.41M | 10.0% | SCHEDULE 13G ↗ |
| Feb 18, 2025 | SCHEDULE 13G | INDP Indaptus Therapeutics, Inc. | Yorkville Advisors Global II, LLC | 1.41M | 10.0% | SCHEDULE 13G ↗ |
| Feb 18, 2025 | SCHEDULE 13G | INDP Indaptus Therapeutics, Inc. | Yorkville Advisors Global, LP | 1.41M | 10.0% | SCHEDULE 13G ↗ |
| Feb 18, 2025 | SCHEDULE 13G | INDP Indaptus Therapeutics, Inc. | YA Global Investments II (U.S.), LP | 1.41M | 10.0% | SCHEDULE 13G ↗ |
| Feb 18, 2025 | SCHEDULE 13G | INDP Indaptus Therapeutics, Inc. | YA II PN, Ltd. | 1.41M | 10.0% | SCHEDULE 13G ↗ |
42 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances